Lifeline Biotechnologies, Inc. (LLBO) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $1.30M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerLifeline Biotechnologies, Inc. (LLBO) trades at $0.0003. Lifeline Biotechnologies, Inc. is a medical technology company focused on early disease detection. Their key product is the First Warning System, a non-invasive breast tissue abnormality detection device. Market cap: $1.30M, Sector: Financials.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for LLBO: LLBO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Lifeline Biotechnologies, Inc. (LLBO) Financial Services Profile
Lifeline Biotechnologies, Inc. develops and markets medical technologies for early disease detection, primarily focusing on breast cancer diagnostics with its First Warning System. The company operates in the competitive medical device sector, emphasizing non-invasive and early detection solutions for improved patient outcomes in the United States and Europe.
What Is the Investment Thesis for LLBO?
Lifeline Biotechnologies, Inc. presents a high-risk, high-reward investment opportunity within the medical device sector. The company's focus on early disease detection, particularly in breast cancer, addresses a significant market need. However, the company's small market capitalization ($1.30M) and negative P/E ratio (-42.18) indicate financial challenges. A key value driver is the potential adoption of the First Warning System, but widespread acceptance hinges on clinical validation and regulatory approvals. Growth catalysts include expanding distribution networks and securing partnerships with healthcare providers. Potential investors should carefully consider the company's financial stability, competitive landscape, and the regulatory hurdles associated with medical device commercialization. The company's high beta of 332.47 suggests extreme volatility.
Based on FMP financials and quantitative analysis
LLBO Key Highlights
Lifeline Biotechnologies, Inc. operates in the medical device industry, focusing on early disease detection technologies.
- The company's primary product is the First Warning System, a non-invasive breast tissue abnormality detection device.
- Lifeline Biotechnologies also offers Mastascope and OVASCOPE, endoscopic devices for breast and ovarian cancer detection, respectively.
- The company has a market capitalization of $1.30M, indicating its small size within the industry.
- Lifeline Biotechnologies, Inc. has a negative P/E ratio of -42.18, reflecting its current lack of profitability.
Who Are LLBO's Competitors?
LLBO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BIOE Bio Essence Corporation | $0.47 | 0.00% | $25.3M | — |
| ASPC A SPAC III Acquisition Corp. | $10.20 | -0.20% | $23.8M | 43 5-pillar |
| BKHA Black Hawk Acquisition Corporation | $6.48 | -24.74% | $26.9M | 47 5-pillar |
| AFJK Aimei Health Technology Co., Ltd | $11.90 | +0.76% | $37.7M | 43 5-pillar |
| AIB AIB Acquisition Corporation | $0.63 | -3.82% | $48.5M | 30 5-pillar |
| PGAC Pantages Capital Acquisition Corporation | $10.87 | -0.09% | $55.8M | 55 5-pillar |
| CHAR Charlton Aria Acquisition Corporation | $10.99 | +0.32% | $57.6M | 46 5-pillar |
| BPAC Bullpen Parlay Acquisition Company | $10.31 | +0.19% | $76.1M | 51 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LLBO's Key Strengths?
Proprietary First Warning System technology.
- Focus on non-invasive and early disease detection.
- Presence in both US and European markets.
- Specialized product portfolio addressing women's health needs.
What Are LLBO's Weaknesses?
Small market capitalization and limited financial resources.
- Negative P/E ratio indicating lack of profitability.
- High beta suggesting significant stock volatility.
- Reliance on a limited number of products.
What Are the Key Risks for LLBO?
Failure to obtain regulatory approvals for its medical devices.
- Intense competition from larger medical device companies.
- Economic downturns affecting healthcare spending.
- Limited financial resources and lack of profitability.
- High stock volatility due to small market capitalization.
What Are LLBO's Competitive Advantages?
- Proprietary technology in non-invasive breast cancer detection with the First Warning System.
- Patents and intellectual property protecting its medical device innovations.
- Established presence in the niche market of early disease detection technologies.
What Does LLBO Do?
Lifeline Biotechnologies, Inc., incorporated in 1981 and headquartered in Reno, Nevada, is a medical technology company dedicated to the prevention, early diagnosis, and rapid recovery from various diseases. The company's flagship product is the First Warning System, a non-invasive, non-compressive, and non-radiogenic device designed to assist in the early detection of breast tissue abnormalities in women. This technology aims to provide a more comfortable and accessible screening option compared to traditional methods. In addition to the First Warning System, Lifeline Biotechnologies offers Mastascope, a handheld endoscope that allows physicians to visualize the interior of the breast through the milk ducts, and OVASCOPE, an ultra-slim endoscope for direct visualization of the ovarian surface to detect cancer. These products represent the company's commitment to innovative diagnostic tools. Lifeline Biotechnologies has operations in both the United States and Europe, reflecting its efforts to expand its market reach and impact. The company focuses on addressing critical needs in women's health through advanced medical technologies.
What Products and Services Does LLBO Offer?
- Develops and markets medical technologies for early disease detection.
- Offers the First Warning System, a non-invasive device for detecting breast tissue abnormalities.
- Provides Mastascope, a handheld endoscope for visualizing the interior of the breast.
- Offers OVASCOPE, an ultra-slim endoscope for direct visualization of the ovarian surface.
- Focuses on prevention, early diagnosis, and quick recovery of various diseases.
- Operates in the United States and Europe.
How Does LLBO Make Money?
- Generates revenue through the sale of its medical devices, including the First Warning System, Mastascope, and OVASCOPE.
- Targets healthcare providers, women's health clinics, and hospitals as primary customers.
- Employs a direct sales force and distribution partnerships to reach its target markets.
What Industry Does LLBO Operate In?
The medical device industry is characterized by rapid innovation, stringent regulatory requirements, and intense competition. Companies like Lifeline Biotechnologies, Inc. operate in a market driven by the increasing demand for early and accurate disease detection methods. The breast cancer diagnostics market, in particular, is experiencing growth due to rising awareness and advancements in technology. However, the industry is also subject to challenges such as high development costs, lengthy approval processes, and the need for continuous product improvement to maintain a competitive edge. Lifeline Biotechnologies competes with larger, more established players in the medical device field, requiring a differentiated approach to gain market share.
Who Are LLBO's Key Customers?
- Women's health clinics
- Hospitals and medical centers
- Healthcare providers specializing in oncology and early disease detection
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
How Lifeline Biotechnologies, Inc. Is Valued
Lifeline Biotechnologies, Inc. carries a market capitalization of $1.30M, placing it in the micro-cap category.
Company Profile
Lifeline Biotechnologies, Inc. operates in the Financial Services sector. It is headquartered in Denton, United States.
LLBO Latest News
No recent news available for LLBO.
LLBO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LLBO.
Price Targets
Wall Street price target analysis for LLBO.
LLBO MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LLBO; grades run from A+ (80-100) to F (below 30).
LLBO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Lifeline Biotechnologies, Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be current in their reporting obligations. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of regulatory oversight and potential for limited information availability compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure due to OTC Other tier status.
- Higher potential for fraud and manipulation compared to listed exchanges.
- Lower liquidity and wider bid-ask spreads.
- Increased price volatility.
- Potential for delisting or trading suspension.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Review the company's capitalization structure and shareholder base.
- Check for any legal or regulatory issues.
- Evaluate the company's liquidity and trading volume.
- Consult with a qualified financial advisor.
- Longevity of the company (incorporated in 1981).
- Focus on a specific niche market (early disease detection).
- Proprietary technology (First Warning System).
- Operations in both US and European markets.
- Presence of patents and intellectual property.
Lifeline Biotechnologies, Inc. Financials Stock: Key Questions Answered
What do analysts say about LLBO stock?
As of 2026-03-16, there is no available analyst coverage for Lifeline Biotechnologies, Inc. (LLBO). The company's small market capitalization and OTC listing may contribute to the lack of analyst interest. Investors should conduct their own thorough research and due diligence before making any investment decisions.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Limited information available on the company's financial performance and future prospects.
- OTC market stocks are inherently more risky than exchange-listed stocks.